Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Inhibition of Anti-Inflammatory Regulator Nrf2 Results in Breast Cancer Retardation In Vitro and In Vivo
Venugopal R. Bovilla, Mahadevaswamy G. Kuruburu, Vidya G. Bettada, et al.
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1119-1119
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Nrf2 Modulation in Breast Cancer
Somayyeh Ghareghomi, Mehran Habibi-Rezaei, Marzia Arese, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2668-2668
Open Access | Times Cited: 63
Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway
Jing Li, Jianchao Zhang, Yan Zhu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8265-8265
Open Access | Times Cited: 18
Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica
Ting He, Fangli Zhou, Anping Su, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114134-114134
Open Access | Times Cited: 24
Variations in the Anticancer Activity of Free and Bound Phenolics of Finger Millet (Eleusine coracana (L) Gaertn; Variety KMR-301) Seeds
Mahadevaswamy G. Kuruburu, Venugopal R. Bovilla, Rimshia Naaz, et al.
Phytomedicine Plus (2022) Vol. 2, Iss. 2, pp. 100276-100276
Open Access | Times Cited: 22
Alkaloids as Natural NRF2 Inhibitors: Chemoprevention and Cytotoxic Action in Cancer
Darinka Gjorgieva Ackova, Viktorija Maksimova, Katarina Smilkov, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 850-850
Open Access | Times Cited: 15
The Transcription Factor NRF2 Has Epigenetic Regulatory Functions Modulating HDACs, DNMTs, and miRNA Biogenesis
Ignacio Silva-Llanes, Chang Hoon Shin, José Jiménez-Villegas, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 641-641
Open Access | Times Cited: 13
RNA m6A involves in regulation of oxidative stress and apoptosis may via NF-kB pathway in cadmium-induced lung cells
Nan Zhang, Jie Yang, Yuan Zhao, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
miR-140-5p Attenuates Hypoxia-Induced Breast Cancer Progression by Targeting Nrf2/HO-1 Axis in a Keap1-Independent Mechanism
Megharani Mahajan, Sandhya L. Sitasawad
Cells (2021) Vol. 11, Iss. 1, pp. 12-12
Open Access | Times Cited: 27
Design, Synthesis, and Anti-Breast Cancer Potential of Imidazole–Pyridine Hybrid Molecules In Vitro and Ehrlich Ascites Carcinoma Growth Inhibitory Activity Assessment In Vivo
Baladhandapani Aruchamy, Mahadevaswamy G. Kuruburu, Venugopal R. Bovilla, et al.
ACS Omega (2023) Vol. 8, Iss. 43, pp. 40287-40298
Open Access | Times Cited: 10
Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway
Wenna Shao, Xinzhao Wang, Zhaoyun Liu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma
Pushkal Sinduvadi Ramesh, Venugopal R. Bovilla, Vikas H. Swamy, et al.
Free Radical Biology and Medicine (2023) Vol. 205, pp. 234-243
Closed Access | Times Cited: 9
Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer
Tayo Alex Adekiya, Madison Moore, Michael A. Thomas, et al.
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 114-114
Open Access | Times Cited: 3
Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor: In vitro Breast Cancer Study
Narasimha M. Beeraka, Jin Zhang, Di Zhao, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 30, pp. 2408-2425
Closed Access | Times Cited: 7
Expression Patterns and Relevance of FN3K, Nrf2, and NQO1 in Breast Cancers
Narasimha M. Beeraka
Eurasian Journal of Medicine and Oncology (2024), pp. 88-105
Open Access | Times Cited: 2
Screening fructosamine-3-kinase (FN3K) inhibitors, a deglycating enzyme of oncogenic Nrf2: Human FN3K homology modelling, docking and molecular dynamics simulations
Narasimha M. Beeraka, Jin Zhang, Subhankar P. Mandal, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0283705-e0283705
Open Access | Times Cited: 6
Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review)
Hiroshi Kobayashi, Shogo Imanaka, Hiroshi Shigetomi
Oncology Letters (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 10
Apigenin attenuates high-fat diet-induced nephropathy in rats by hypoglycemic and hypolipidemic effects, and concomitant activation of the Nrf2/antioxidant axis
Tahany Saleh Aldayel
Journal of Functional Foods (2022) Vol. 99, pp. 105295-105295
Open Access | Times Cited: 10
Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1
Zhang’an Dai, Lin Cai, Yingyu Chen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 14
Brusatol inhibits the growth of prostate cancer cells and reduces HIF-1α/VEGF expression and glycolysis under hypoxia
Mi Wang, Li‐Yang Dai, Wei Yan, et al.
Quality Assurance and Safety of Crops & Foods (2022) Vol. 14, Iss. 4, pp. 13-22
Open Access | Times Cited: 8
In Silico Analysis Determining the Binding Interactions of NAD(P)H: Quinone Oxidoreductase 1 and Resveratrol via Docking and Molecular Dynamic Simulations
Santosh Kumar Behera, Christoffer Briggs Lambring, Albina Hashmi, et al.
European Journal of Biology (2023)
Open Access | Times Cited: 4
Polydatin: A natural compound with multifaceted anticancer properties
Khalid Imtiyaz, M Shafi, Khalid Umar Fakhri, et al.
Journal of Traditional and Complementary Medicine (2024)
Open Access | Times Cited: 1
Targeting the Key Enzymes of Abnormal Fatty Acid β-oxidation as a Potential Strategy for Tumor Therapy
Hongdan Chen, Zeyu Yang, Yiceng Sun, et al.
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 3
Open Access | Times Cited: 6
Isoliquiritigenin attenuates high-fat diet-induced intestinal damage by suppressing inflammation and oxidative stress and through activating Nrf2
Mohammed Abdo Yahya, Ghedeir M. Alshammari, Magdi A. Osman, et al.
Journal of Functional Foods (2022) Vol. 92, pp. 105058-105058
Open Access | Times Cited: 6
Interplay between Non-Coding RNAs and NRF2 in Different Cancers: Spotlight on MicroRNAs and Long Non-Coding RNAs
İlhan Yaylım, Ammad Ahmad Farooqı, Pelin Telkoparan‐Akillilar, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 384, Iss. 1, pp. 28-34
Open Access | Times Cited: 6
Identification of the Brucea javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay
Chonticha Suwattanasophon, Agnes T. Reiner, Jon Alberdi-Cedeño, et al.
ACS Omega (2023) Vol. 8, Iss. 31, pp. 28543-28552
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top